IL6 and congenital rubella syndrome: The most well-addressed side effect of novel immunological therapies is represented by cytokine release syndrome (CRS), consisting of a non-specific and abnormal activation of the immune system with the release of cytokines such as TNFα, IL-6 and IFNγ, and further activation of lymphocytes and myeloid cells.